Pharmacokinetic studies on CI-981 (3) - In vitro and in vivo plasma protein binding -

Japanese Pharmacology and Therapeutics

Volumn 26, Issue 8, 1998, Pages 55-66

  Nemoto, Hiroyuki ^a   Oyama, Toshihiro ^a   Karasawa, Yoshio ^a   Esumi, Yoshio ^a   Watanabe, Masako ^b   Kaneko, Kiyohisa ^b   Oishi, Shimako ^c  

^a DAIICHI PURE CHEMICALS CO LTD   (Japan)

^b Parke Davis Pharmaceuticals   (Japan)

^c INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

Author keywords

Antihyperlipidemic agent; Atorvastatin; CI 981; Dog; HMG CoA reductase inhibitor; Human; Mouse; Plasma protein binding; Rat

Indexed keywords

ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CARBON 14; DILTIAZEM; GLIBENCLAMIDE;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; HUMAN; ISOTOPE LABELING; NONHUMAN;

EID: 0031662150     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bocan TMA et al: Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981; Comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1123: 133-144, 1992
2. Krause BR, Newton RS: Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 117: 237-244, 1995
3. Bakker-Arkema RG et al: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128-133, 1996
4. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group: Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 79: 1248-1252, 1997
5. Winkler H et al: High-performance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue. J Chromatogr 228: 223-234, 1982
6. Endele R: A gas chromatographic method for the determination of bezafibrate in serum and urine. J Chromatogr 154: 261-263, 1978
7. Fluvastatin. 10(4): 513-528, 1995
8. Simvastatin 5(2): 133-149, 1990
9. Ferner RE et al: Pharmacokinetics and toxic effects of diltiazem in massive overdose. Human Toxicology 8: 497-499, 1989
10. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th ed, p 1659, 1993
11. Monk JP, Todd PA: Bezafibrate; A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia. Drugs 33: 539-576, 1987
12. McBurnesy GA, Cole A: Possible protein binding displacement interaction between glibenclamide and metolazone. Eur J Clin Pharmacol 38: 93-95, 1990
13. Bloedow DC et al: Serum binding of diltiazem in humans. J Clin Pharmacol 22: 201-205, 1982
14. Barber HE et al: Protein binding of atenolol and propranolol to human serum albumin and in human plasma. Br J Clin Pharmacol 6: 446p-447p, 1978
15. Belpaire FM, Bogaert MG: Serum binding of diltiazem in humans. Acta Cardiol 45: 167, 1990
16. Lozada A, Dujovne CA: Drug interactions with fibric acids. Pharmac Ther 63: 163-176, 1994
17. Crooks MJ, Brown KF: The binding of sulphonylureas to serum albumin. J Pharm Pharmacol 26: 304-311, 1974